IHE — iShares U.S. Pharmaceuticals ETF
Data updated: 2026-08-24
IHE — iShares U.S. Pharmaceuticals ETF. United States Large Cap Blend / Core Health Care Equity · $1.14B AUM. Holdings, fees, performance and SEC filings.
IHE Fund Overview
IHE — iShares U.S. Pharmaceuticals ETF is a US ETF managed by iSHARES TRUST, categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: iSHARES TRUST
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $1.14B
- 1-year return: 53.7%
- Ticker: IHE
- SEC CIK: 0001100663
- SEC series ID: S000009417
- Share class ID: C000025771
IHE Holdings
Top 10 holdings of iShares U.S. Pharmaceuticals ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Johnson & Johnson | 22.44% |
| Eli Lilly And Company | 22.25% |
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 6.24% |
| Merck & Co., Inc. | 4.55% |
| Bristol-Myers Squibb Company | 4.37% |
| Royalty Pharma PLC | 4.33% |
| Viatris Inc. | 4.22% |
| Pfizer Inc. | 3.96% |
| Zoetis Inc. | 3.73% |
| Jazz Pharmaceuticals Public Limited Company | 3.45% |
IHE Portfolio Allocation
Asset-class allocation of iShares U.S. Pharmaceuticals ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 6.3% |
IHE Performance
Total returns for IHE (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 17.5% |
| 1 year | 53.7% |
| 3 years (annualised) | 20.4% |
| 5 years (annualised) | 11.8% |
IHE Risk Information
Risk metrics for IHE, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.2%
IHE Costs and Fees
IHE costs about $38 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.38%
- Gross expense ratio: 0.38%
- Portfolio turnover: 24%
- Brokerage commissions: 0.87 bps of average net assets (SEC N-CEN)
IHE Cashflows
Over the 12 months to 2026-06, iShares U.S. Pharmaceuticals ETF had net inflows of $280.16M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $148.45M |
| 2026-05 | −$75.11M |
| 2026-04 | −$65.16M |
| 2026-03 | −$4.63M |
| 2026-02 | $35.81M |
| 2026-01 | $101.55M |
IHE Debt Constituents
No individual debt constituents are reported in iShares U.S. Pharmaceuticals ETF's latest SEC N-PORT filing.
IHE Prospectus and SEC Filings
Official iShares U.S. Pharmaceuticals ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-07-22
- Prospectus (485BPOS) — filed 2024-07-19
- Prospectus (485BPOS) — filed 2023-07-20
- Portfolio holdings (N-PORT) — filed 2026-08-24
- Portfolio holdings (N-PORT) — filed 2026-05-22
- Portfolio holdings (N-PORT) — filed 2026-02-23
- Annual census (N-CEN) — filed 2026-06-15
- Annual census (N-CEN) — filed 2025-06-13
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.